FDA Clearance Tracker · P120016-S024
VASCADE MVP Venous Vascular Closure System (VVCS)
Last checked: Nov 20, 2026Latest source record: Nov 27, 2018 (this decision)Source: openFDAMethods & limitations
Decided
Nov 27, 2018
Approved
Time to decision
181 days
Received May 30, 2018. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P120016-S024
- Device name
- VASCADE MVP Venous Vascular Closure System (VVCS)
- Applicant
- Cardiva Medical, Inc.
- Applicant location
- Santa Clara, CA
- Received
- May 30, 2018
- Decided
- Nov 27, 2018
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P120016
Device type
- Device type
- Device, hemostasis, vascular (MGB)
- Device class
- Class III
- Specialty
- Cardiology
FDA's approval statement
As written in FDA's record.
Approval for percutaneous closure of femoral venous access sites while reducing time to ambulation, total post-procedure time, time to hemostasis, and time to discharge eligibility in patients who have undergone catheter-based procedures utilizing 6-12F inner diameter procedural sheaths, with single or multiple access sites in one or both limbs.
Source documents
Other decisions for Cardiva Medical, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- VASCADE MVP XL VVCS Model 800-1014XLPMA supplement
P120016-S039 · Decided Mar 27, 2026 · 178 days after receipt · Panel Track
Device type: Device, hemostasis, vascular (MGB) · Cardiology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.